Compare Cytokinetics Inc (CYTK) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Western Alliance Bancorporation — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Western Alliance Bancorporation trades at $81.46 (market cap $8.78B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Western Alliance Bancorporation pays a 2.09% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | WAL | |
|---|---|---|
Market Cap | $10.78B | $8.78B |
Sector | Technology | Financials |
52-Week High | $87.26 | $96.08 |
52-Week Low | $33.23 | $66.70 |
Enterprise Value | $10.88B | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Western Alliance Bancorporation (WAL) trades at $81.39, up 0.06% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals with a P/E of 9.08, net income margin of 25.43%, and consistent earnings beats in recent quarters. Recent developments include the launch of WA VenueX, a digital asset liquidity platform, and recognition as Arizona's top bank by Forbes in 2026.
Outlook remains positive with a consensus price target of $93.86, implying 15% upside, supported by 79% analyst buy ratings. Risks include negative operating cash flow and institutional selling, but revenue growth and profitability trends provide a solid foundation for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
